Abstract:The N-glycan pattern of an IgG antibody, attached at a conserved site within the Fc region, is a critical antibody quality attribute whose structural variability can also impact antibody function. For tailoring the Fc glycoprofile, glycoengineering in cell lines as well as Fc amino acid mutations have been applied. Multiple glycoengineered CHO cell lines were generated, including defucosylated (FUT8KO), α-2,6-sialylated (ST6KI) and defucosylated α-2,6-sialylated (FUT8KOST6KI), expressing either a wild-type anti-CD20 IgG (WT) or phenylalanine to alanine (F241A) mutant. MALDI-TOF MS characterization of antibody N-glycans revealed that the F241A mutation significantly increased galactosylation and sialylation content and glycan branching. Furthermore, overexpression of recombinant human α-2,6-sialyltransferase resulted in a predominance of α-2,6-sialylation rather than α-2,3-sialylation for both wild-type and heavily sialylated F241A antibody N-glycans. Interestingly, knocking out α-1,6-fucosyltransferase (FUT8KO), which removed core fucose, lowered the content of N-glycans with terminal Gal and increased levels of terminal GlcNAc and Man5 groups on WT antibody. Further complement-dependent cytotoxicity (CDC) analysis revealed that, regardless of the production cells, WT antibody samples have higher cytotoxic CDC activity with more exposed Gal residues compared to their individual F241A mutants. However, the FUT8KO WT antibody, with a large fraction of bi-GlcNAc structures (G0), displayed the lowest CDC activity of all WT antibody samples. Furthermore, for the F241A mutants, a higher CDC activity was observed for α-2,6- compared to α-2,3-sialylation. Antibody-dependent cellular cytotoxicity (ADCC) analysis revealed that the defucosylated WT and F241A mutants showed enhanced in vitro ADCC performance compared to their fucosylated counterparts, with the defucosylated WT antibodies displaying the highest overall ADCC activity, regardless of sialic acid substitution. Moreover, the FcγRIIIA receptor binding by antibodies did not always correspond directly with ADCC result. This study demonstrates that glycoengineering and protein engineering can both promote and inhibit antibody effector functions and represent practical approaches for varying glycan composition and functionalities during antibody development.This article is protected by copyright. All rights reserved.

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped During Glycan Biosynthesis

Molecular Insights into the Binding Selectivity of a Synthetic Ligand DAAG to Fc Fragment of IgG

Effects of Anchor Structure and Glycosylation of Fc Gamma Receptor Iii on Ligand Binding Affinity

Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies

Modulating antibody effector functions by Fc glycoengineering

The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions

Influence of glycan modification on IgG1 biochemical and biophysical properties

Covalent and Oriented Immobilization of Scfv Antibody Fragments Via an Engineered Glycan Moiety

Effects of N-glycans on the structure of human IgA2

Trimming Crystallizable Fragment (fc) Glycans Enables the Direct Enzymatic Transfer of Biomacromolecules to Antibodies As Therapeutics.

Structural Insights into Immunoglobulin M

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities

Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment

NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation.

Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Impact of structural modifications of IgG antibodies on effector functions

Post-translational structural modifications of immunoglobulin G and their effect on biological activity

Experimental and Computational Insights into the Structural Dynamics of the Fc Fragment of IgG1 Subtype from Biosimilar VEGF-Trap

Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes

Unfolding of IgG domains detected by non-reducing SDS-PAGE